secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-089281
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q2 net loss $26.9M; LIFT-AD topline data expected Sept 2024
-------------------------------------------------------------------------

- Cash, cash equivalents and investments were $91.8M as of June 30, 2024, down from $147.4M at Dec 31, 2023.
- Net loss of $26.9M ($0.70 per share) for Q2 2024 vs. $29.6M ($0.78 per share) in Q2 2023.
- R&D expenses $22.2M (up from $21.6M) driven by ATH-1105 Phase 1 trial; G&A down to $5.9M from $10.0M.
- Topline data from Phase 2/3 LIFT-AD trial of fosgonimeton in Alzheimer's targeted for September 2024; full data at CTAD in October.
- Phase 1 trial of oral ATH-1105 for ALS underway; first cohort completed, expected completion by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024089281/0000950170-24-089281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024089281/atha-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer